Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis
Apolipoproteins
Inflammatory mediators
Lipids
PLS-DA
Journal
SLAS technology
ISSN: 2472-6311
Titre abrégé: SLAS Technol
Pays: United States
ID NLM: 101697564
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
16
05
2022
revised:
20
07
2022
accepted:
24
07
2022
pubmed:
1
8
2022
medline:
12
10
2022
entrez:
31
7
2022
Statut:
ppublish
Résumé
There is currently no diagnostic or prognostic biomarker available in clinical practice for Amyotrophic Lateral Sclerosis (ALS). The objective of this study was to monitor a combination of various inflammatory markers, lipids, and apolipoproteins alterations in ALS patients at the time of diagnosis, to assess their role as early diagnostic or prognostic biomarker candidates. C-reactive protein, orosomucoid, prealbumin, calprotectin, lipids and apoliproteins were determined in the blood of all subjects (25 ALS patients, 23 controls) as routinely performed in our laboratory. Inflammatory mediators were evaluated by a bead-based multiplex assay. A two-step approach was used for each analytical strategy: univariate analysis followed by multivariate analysis. Eight features were significantly different between ALS patients and controls, sometimes with important fold changes. The supervised Partial least Squares Discriminant Analysis separated ALS and controls with great accuracy (94 %) and the permutation test was significant (p < 0.01), ensuring the robustness of the model. The prediction model leads to a mean sensitivity and specificity of 90 (+/- 10) and 78 (+/- 10) %, respectively, with a mean predictive positive value and negative predictive value of 80 (+/- 8.9) and 89 (+/- 11.8) %, respectively. However, the models did not discriminate subgroups of ALS patients based on ALS characteristics. This study highlights the usefulness of evaluating a combination of multiple pathways rather than focusing on a single target. These promising results suggest the need for the longitudinal monitoring of these candidates to determine their role in disease evolution.
Identifiants
pubmed: 35908647
pii: S2472-6303(22)05165-2
doi: 10.1016/j.slast.2022.07.003
pii:
doi:
Substances chimiques
Apolipoproteins
0
Biomarkers
0
Inflammation Mediators
0
Leukocyte L1 Antigen Complex
0
Lipids
0
Lipoproteins
0
Orosomucoid
0
Prealbumin
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-334Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.